Global Blood Therapeutics Inc. (NASDAQ:GBT) posted its quarterly earnings results on Wednesday. The company reported ($0.58) EPS for the quarter, meeting the consensus estimate of ($0.58). During the same period in the previous year, the firm posted ($0.90) earnings per share.

Shares of Global Blood Therapeutics (NASDAQ:GBT) opened at 18.75 on Friday. Global Blood Therapeutics has a one year low of $12.24 and a one year high of $55.74. The stock’s market cap is $699.09 million. The stock’s 50 day moving average price is $19.05 and its 200-day moving average price is $19.32.

Several large investors have recently made changes to their positions in GBT. American International Group Inc. increased its stake in shares of Global Blood Therapeutics by 104.2% in the second quarter. American International Group Inc. now owns 8,096 shares of the company’s stock valued at $134,000 after buying an additional 4,131 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of Global Blood Therapeutics by 101.7% in the second quarter. Nationwide Fund Advisors now owns 9,100 shares of the company’s stock valued at $151,000 after buying an additional 4,588 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of Global Blood Therapeutics during the second quarter valued at approximately $194,000. New York State Common Retirement Fund increased its stake in shares of Global Blood Therapeutics by 40.3% in the third quarter. New York State Common Retirement Fund now owns 20,200 shares of the company’s stock valued at $466,000 after buying an additional 5,800 shares in the last quarter. Finally, Teachers Advisors Inc. increased its stake in shares of Global Blood Therapeutics by 122.2% in the second quarter. Teachers Advisors Inc. now owns 22,272 shares of the company’s stock valued at $369,000 after buying an additional 12,247 shares in the last quarter. 62.37% of the stock is owned by institutional investors and hedge funds.

Several analysts have commented on the company. Morgan Stanley restated a “buy” rating and issued a $62.00 price target on shares of Global Blood Therapeutics in a report on Sunday, August 14th. Wells Fargo & Co. assumed coverage on Global Blood Therapeutics in a report on Friday, September 30th. They issued an “outperform” rating and a $23.05 price target for the company. Cowen and Company restated an “outperform” rating and issued a $83.00 price target (up previously from $80.00) on shares of Global Blood Therapeutics in a report on Wednesday, October 26th. Wedbush restated an “outperform” rating and issued a $66.00 price target on shares of Global Blood Therapeutics in a report on Monday, August 22nd. Finally, Zacks Investment Research upgraded Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $21.00 price target for the company in a report on Thursday, October 27th. Six analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $47.86.

Global Blood Therapeutics Company Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company’s segment is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders.

5 Day Chart for NASDAQ:GBT

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.